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Abstract
Aristolochic acid (AA), a mixture of aristolochic acid I (AAI) and aristolochic acid II (AAII), is present in Aristolochiaceae
plants, many of which are used as herbal folk remedies. Plants containing AA, however, can be nephrotoxic, genotoxic and carcinogenic in humans. AA has been also associated with the development of tumors in mice and rats. Therefore, plant products containing AA have been banned in many countries. Because quantitative cancer risk assessment is based upon an understanding of the
chemical’s mode-of-action, it is necessary to determine whether the chemical is a mutagenic carcinogen. In this review, we present
the available information concerning the genotoxicity of AA and discuss the possible mechanisms for mutation induction by AA.
The evidences indicate that AA is mutagenic and this activity is mediated mainly by the formation of AA-DNA adducts. Not only
does AA induce genetic damage and mutations in bacteria, mammalian cells, Drosophila, and rodents, but it is also demonstrated
to induce mutations in the target tissues of the model animals and oncogenes from human. Many evidences from genotoxicity tests
also indicate that AA is a clastogenic agent that breaks DNA and results in chromosome damage and chromosome mutations. These
results indicate that AA is a mutagenic carcinogen.
Key words: aristolochic acid, genotoxicity, DNA adduct, clastogenicity, mutation, mutagenicity, oncogene

Introduction
Aristolochic acid (AA, CAS No. 10190-99-5) is a
mixture of aristolochic acid I (AAI, 3,4-methylenedioxy-8methoxy-10-nitrophenanthrene-1-carboxylic acid, molecular weight 341.276, CAS No. 313-67-7) and aristolochic
acid II (AAII, 3,4-methylenedioxy-10-nitrophenanthrene-1carboxylic acid, molecular weight 311.250, CAS No. 47580-9)(1) (Figure 1). AA is an active component of herbal
drugs derived from Aristolochiaceae family of plants.
These herbal drugs containing AA have been used for
medicine purposes since antiquity worldwide, such as for
treatment of snake bites, arthritis, gout, rheumatism, and
festering wounds, as well as used in obstetrics(2-8).
Plants containing AA, however, can be nephrotoxic, genotoxic and carcinogenic in humans(7,9-19). In the
early 1992, cases of so-called Chinese herbs nephropathy
(CHN), more appropriately replaced later by aristolochic
acid nephropathy (AAN)(20) were reported in Belgium(21).
An outbreak of rapidly progressive renal fibrosis in
Belgium involved at least 100 patients, mostly middle-aged
women undergoing a weight-loss regimen that included
use of a mixture of Chinese herbs containing Aristolochia
species incorrectly labeled as Stephania tetrandra. About
half of these AAN patients had renal replacement therapy(21-25). Similar AAN cases subsequently were observed
* Author for correspondence. Tel: +870-543-7954;
Fax: +870-543-7682; E-mail: tao.chen@fda.hhs.gov

in many countries and repeatedly reported(26-34). Soon
thereafter, AA-associated urothelial cancer was reported,
with near 50% incidence of upper urinary tract urothelial
malignancy found in Belgian AAN patients(9,35,36). Invasive urothelial carcinoma also were reported in patients
without severe renal failure after exposure to Chinese
herbal medicine containing AA(37,38). AA is also associated to the etiology of Balkan endemic nephropathy-associated urothelial cancer(39). Specific AA-derived DNA
adducts were found in the kidney, ureter, bladder, liver,
lung, and spleen of the AAN patients(40-42), providing
strong evidence linking the use of herbal products containing AA with cancer development.
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Figure 1. Chemical structural of aristolochic acids I (R = OCH3) and
II (R = H).
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urinary tract (19). Rats given daily doses of 10 mg/kg AA
for 35 days developed papillary urothelial carcinoma by
day 105(45). In mice, AA treatment results in squamous
cell carcinoma of the forestomach, adenocarcinoma of
the glandular stomach, kidney adenomas, lung carcinomas, and uterine haemangiomas (17). AA is found among
the most potent 2% of the carcinogens in Carcinogenic
Potency and Genotoxicity Databases (46).
Based on evidences from humans and animals, the
International Agency for Research on Cancer (IARC) has
classified herbal remedies containing plant species of the
genus Aristolochia as human carcinogens (Group I)(47).
Several countries including United Kingdom, Canada,

Animal studies show that AA results in renal failure in rodents (11) and induces tumors in the kidney and
other tissues of rabbits, rats and mice (16,17,19,43,44). When
rabbits were injected intraperitoneally with 0.1 mg/kg
of AA 5 days per week for 17 to 21 months, 25% developed severe hypocellular interstitial fibrosis, urothelial
dysplasia, and tumors of the urinary tract (44). Longterm oral treatment of mice and rats with AA resulted
in the time- and dose-dependent induction of tumors in
multiple tissues. When AA was administered orally to
rats for 3 months in doses ranging from 0.1 to 10.0 mg/
kg, the animals developed squamous cell carcinomas in
the forestomach and malignant tumors in the kidney and
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Figure 2. Metabolic activation of aristolochic acid (AA) and AA-DNA adduct formation. Data are from literatures(27,56-58,69). [R] means
reduction and [O] represents oxidation.
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Australia, and Germany banned the use of herbs containing AA(48). The U.S. Food and Drug Administration
issued a Consumer Advisory in 2001 warning consumers against using dietary supplements and other botanical
products containing AA and requesting a recall of these
products and published a list of botanical products that
contained AA(49).
Despite the actions of the FDA and other agencies,
products containing AA have not been banned in the
USA and many other countries. Many products containing or suspected to contain AA are still available in
market or on web sites for sale for gastrointestinal symptoms, weight loss, cough, immune stimulation and other
purposes (29,50-52). The Dutch Food and Consumer Product Safety Authority investigated 190 Chinese traditional
herbal preparations potentially containing AA between
2002 and 2006 in the Dutch market. AAI was found in
25 samples up to a concentration of 1,676 mg/kg. AAII
was also found in 13 of these samples up to 444 mg/kg.
These positive samples contained Mu Tong, Fang Ji, Tian
Xian Teng or Xi Xin. In a worst-case scenario, use of
a sample of Mu Tong with the highest AA content over
a 7-day period would result in the same intake levels of
AA that significantly raised the cancer risk in the Belgian
AAN cases (51).
It has been reported that AA-initiated tumors are
associated with activation of H-ras oncogene and inactivation of p53 tumor suppressor gene by AA-specific A:T
→ T:A transversion mutations (41,53,54), suggesting a genotoxic mechanism for mode of action of AA carcinogenesis. Genotoxicity of AA has been widely studied and the
generated data demonstrate that AA is a potent mutagen.
However, no review article specific to genotoxicity of AA
has been published although AA and AAN have been
extensively reviewed (27,28). The purpose of this review
is to present the knowledge regarding the genotoxicity of
AA.

DNA and chromosome damage
induced by aristolochic acid
I. DNA Adducts Formed by AA
Metabolism studies demonstrate that the major
metabolites of AAI and AAII in vitro and in vivo are
aristolactam I and II(55,56). These metabolites can
undergo reduction of the nitro group to form reactive
cyclic nitrenium ions that are able to form covalent DNA
adducts with the exocyclic amino groups of adenine and
guanine (57-59) (Figure 2). Human P450 1A1, P450 1A2,
nitroreductases, preoxidases and sulphotransferases were
found capable of activating AA(60-68).
AA-DNA adducts have been induced in the tissues of
both exposed humans and rodents(40-42,58,69,70), which are
summarized in Table 1. Four major types of purine AADNA adducts have been detected by 32P-postlabelling
assay(57-59). They are 7-(deoxyadenosin-N6 -yl)aristolactam
I (dA-AAI), 7-(deoxyguanosin-N2-yl)aristolactam I (dGAAI), 7-(deoxyadenosin-N6 -yl)aristolactam II (dA-AAII)
and 7-(deoxyguanosin-N2-yl)aristolactam II (dG-AAII).
dA-AAI, dA-AAII, and dG-AAI were the major DNA
adducts found in the forestomach, glandular stomach,
liver, kidney and urinary bladder epithelium of rats treated with AA(58,70,71). The three adducts were present at
similar concentrations in liver, while more dG-AAI and
dA-AAII adducts were detected than dA-AAI adducts in
kidney. Kidney had at least 2-fold more AA-induced DNA
adducts than liver(70). In human, dA-AAI was the most
abundant AA-DNA adduct found in urothelial tissue and
other tissues of the AAN patients(9,42,72) because this AADNA adduct was the most persistent and the samples were
examined a long period after exposure of AA. It has been
reported that dA-AAI was detectable even 8 years after
the Belgian AAN patients stopped taking the herbal slimming regimen(9). The persistence of DNA adducts has been

Table 1. DNA adducts formatted by aristolochic acid
Agent

Type of DNA adduct

Tissue

Reference

Aristolochia fangchi

dA-AAI, dA-AAII, dG-AAI

Human kidney, ureter, bladder, lung and spleen

(9, 40-42, 72)

AA

dA-AAI, dA-AAII, dG-AAI

Rat liver and kidney

(70, 71)

AAI

dA-AAI, dG-AAI,

Rat forestomach, glandular stomach, liver,
kidney and urinary bladder epithelium

(58, 73)

AAII

dA-AAII

Rat liver, stomach, kidney and bladder

(58, 59)

AAI

dA-AAI, dG-AAI

Mouse liver, stomach, kidney, lung, spleen,
intestine, and bladder

(75)

AAII

dA-AAII, dG-AAII

Mouse liver, stomach, kidney, lung, spleen,
intestine, and bladder

(75)

Abbreviation: aristolochic acid, AA; aristolochic acid I, AAI; aristolochic acid II, AAII; 7-(deoxyadenosin-N6 -yl)aristolactam I, dA-AAI; 7(deoxyguanosin-N2-yl)aristolactam I, dG-AAI; 7-(deoxyadenosin-N6 -yl)aristolactam II, dA-AAII; and 7-(deoxyguanosin-N2-yl)aristolactam
II, dG-AAII.
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investigated in several rat organs after a single oral dose of
pure AAI(72,73). Both dG-AAI and dA-AAI adducts rapidly
decrease during the first 2 weeks. While dG-AAI adducts
continued to disappear, dA-AAI levels remain practically
unchanged between 4 and 36 weeks in the target and nontarget tissues. It was suggested that the persistent dA-AAI
adducts may occupy specific genomic sites that are not
amenable to repair and that these adducts may be converted
into mutations more than other types of AA-DNA adducts
due to its persistence(72) .
AAI was found more cytotoxic than AAII while other
structural analogues either have less overall toxicity or no
toxicity comparing to AAI and AAII(74). However, it has
also been suggested that AAI and AAII have similar genotoxic and carcinogenic potential(75). To compare the genotoxicities of AAI and AAII, Shibutani and his colleagues
treated mice with AAI and AAII, respectively. They found
similar levels of DNA adducts derived from AAI and AAII
in the target tissues, kidney and bladder, although the
levels of the DNA adducts derived from AAI were significantly higher than those derived from AAII in non-target
tissues, the liver, stomach, intestine and lung(75).
II. DNA Strand Breakage
Comet assay can be used to measure DNA fragments
generated by DNA double strand breaks and single strand
breaks. Three recent studies using comet assays demonstrate that AA can cause DNA damage via breaking the
DNA (Table 2). In an in vivo comet assay with isolated nuclei from kidney cells, AA treatment significantly
increased the DNA fragmentation in animals treated once
with 20 or 40 mg AA/kg body weight by gavage in a 22–
26 hour expression period(76). In an in vitro comet assay

using HepG2 cells, AA caused a significant induction of
DNA breakage in a dose-dependent manner at concentrations 25–200 μM(77). In the other in vitro study, Li et al.
investigated the effect of AAI on DNA damage and cell
cycle in porcine proximal tubular epithelial cell lines (78).
The cells were treated with AAI at the concentrations of
80, 320, and 1,280 ng/mL for 24 hr. DNA damage was
examined by comet assay; and the cell cycle was assayed
by flow cytometry. They found that AAI-induced DNA
breakage prior to apoptosis and lysis in the treated cells
in a dose-dependent manner and that the percentage of
cells in the G2/M phase increased significantly. The
authors suggested that AAI might cause DNA damage
and cell cycle arrest through a wild-type p53-independent
pathway prior to apoptosis or necrosis.
III. Micronucleus Analysis
Micronucleus induction by AA has been widely
reported (Table 2). Mengs and Klein (79) measured genotoxic effects of AA using the micronucleus test on bone
marrow cells. Male and female mice were given a single
intravenous injection of 6, 20, or 60 mg/kg, respectively.
Within 48 hr of administration, the males treated with 6
mg/kg or over and the females given 20 mg/kg or over
showed statistically significant increases in the numbers
of micronucleated polychromatic erythrocytes over the
negative control. Kohara et al.(80) analyzed the clastogenicity of AA by evaluating the peripheral blood micronucleus after intragastric treatment of 15 mg AA/kg body
weight per week for 4 weeks. However, no statistical
difference in frequency of micronucleated reticulocytes
was observed. This results was similar to a previous
report for other strains of mice (81). Different doses and

Table 2. Clastogenic effects of aristolochic acid
Agent

Test system

Result

Reference

AA

In vivo comet assay on isolated kidney cells

Positive

(76)

AA

In vitro comet assay using HepG2 cells

Positive

(77)

AAI

In vitro comet assay using tubular epithelial cells

Positive

(78)

AA

Micronucleus test in mouse bone marrow

Positive

(79)

AA

Micronucleus test in mouse peripheral blood

Negative

(80, 81)

AA

Micronucleus test in CHO cells with or without S9

Positive

(15)

AA

Micronucleus test in Hep-G2 cells with or without S9

Positive

(77, 82)

AA

In vitro micronucleus test in human lymphocytes with or without S9

Positive

(82)

AA

In vitro sister chromatid exchanges in human lymphocytes

Positive

(83)

AA

In vitro chromosome aberration in human lymphocytes

Positive

(83)

AA

Chromosomal aberration in CHO cells with or without S9

Positive

(15)

AA

In vivo treatment and in vitro culture unscheduled DNA synthesis test in
stomach pyloric mucosa of rats

Negative

(84)

AA

Chromosome loss in male germ cells of Drosophila melanogaster

Positive

(85)

Abbreviation: aristolochic acid, AA; aristolochic acid I, AAI; aristolochic acid II, AAII.
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routes of administration were suggested for the different
results from the mouse tests (80).
Several in vitro studies also showed that AA was
a clastogenic agent in micronucleus assays. Significant increases in micronucleated binucleated cells were
observed in CHO cells treated with AA at ≥ 25 µg/mL
with or without S9(15). Wu et al. studied induction of
micronuclei by AA in the metabolically competent human
hepatoma cell line HepG2 cells and found a significant increase of the micronuclei frequency in the range
between 12.5 and 50 μM in the micronucleus test (77).
Also, AA caused a significant increase in the number of
micronuclei in human lymphocytes in the presence and
the absence of rat liver S9-mix and in HepG2(82).
IV. Chromosome Damage
Chromosomal damage caused by AA has been
summarized in Table 2. Abel and Schimmer investigated the induction of structural chromosome aberrations
and sister chromatid exchanges (SCEs) by AA in human
lymphocytes (83). Cells were treated with a range of 1 to
20 mg AA /mL for the throughout culture time or during
the G 0 phase of the cell cycle. Both treatment conditions resulted in significant chromosome damage. The
induction of chromosome gaps and breaks and SCEs was
dose-dependent. The number of SCEs per metaphase was
enhanced by a factor of 2 to 3.
The ability of AA to induce chromosomal aberrations was evaluated in CHO cells with or without S9(15).
The cells were treated with five concentrations of AA
covering a range of 6.25–100 μg/mL. AA produced dosedependent increases in the frequency of the structural
chromosomal aberrations, with statistically significant
increases observed at 25.0 and 50.0 μg/mL.
Unscheduled DNA synthesis in stomach pyloric
mucosa of rats was examined in in vitro organ cultures
after administration of AA in vivo and the test was negative (84). AA was also tested with Drosophila melanogaster and the treatment of AA resulted in significant chromosome losses in male germ cells (85).

Mutagenicity of aristolochic acid
The mutagenicity results of AA from testing in
bacteria, mammalian cells, Drosophina, rodents and
oncogenes have been summarized in Table 3.
I. Mutagenicity in Bacteria
AA was mutagenic to Salmonella typhimurium (14,15,55,60,86-88). Although AA was a direct-acting
mutagen in strains TA100, TA102, TA1537 and TM677, it
was a week mutagen to TA98(15,87,88). AAI was found not
active in the nitroreductases-deficient strains TA98NR
and TA100NR, indicating the necessity of nitroreduc-

tion for the bioactivation of AAI(86,87). The mutagenicity of AA was strongly reduced, usually completely abolished, in the strains that were deficient in an endogenous
nitroreductases (14,87). Gotzl et al. studied mutagenicities
of AAI and AAII in S. typhimurium tester strains that
contained multicopy plasmids carrying the genes for the
classical bacterial nitroreductase. They concluded from
their study that only the nitro group is important for the
mutagenicity of AA in S. typhimurium; AAII was more
efficiently metabolized by endogenous nitroreductases
than AAI; and the methoxy group is probably responsible
for the lower activity of AAI, producing steric hindrance
for binding of the genetically active intermediate to DNA
or for binding of the substrate to the active site of the
enzyme(s)(88).
AA, AAI and AAII were tested for genotoxicity, respectively, using Escherichia coli PQ37 genotoxicity assay (SOS chromotest) in the presence and in the
absence of an exogenous metabolizing system. AA, AAI,
and AAII, were genotoxic in the SOS chromotest in the
absence of S9-mix, while AA and AAI showed genotoxic
effects and AAII was marginal genotoxic effects in the
presence of an exogenous metabolizing system(89).
II. Gene Mutations in Mammalian Cells
AA was mutagenic to mouse lymphoma L5178Y cells
in both the presence and absence of S9 activation system.
Mutations were induced by AA in mouse lymphoma cells
at concentrations of 25 μg/mL and above. Percentage of
small Tk mutant colonies increased with AA concentrations, indicating that AA might produce more chromosomal damages than point mutations at high cytotoxicity(15). Also, both AAI and AAII were direct mutagens
in the Hprt gene when evaluated with cultured Chinese
hamster ovary cells (87).
Maier et al. evaluated the mutagenic potencies of
AAI and AAII using a Hprt mutation assay in the subcutaneous connective tissue in vitro. The oxygen tension
in vitro was adjusted to that found in vivo. The results
showed that AAI was 19 times more mutagenic than AAII
at this low oxygen tension, but only 4 times greater than
AAII under standard culture conditions. The authors
concluded that the genotoxicity of AA in vivo was mainly
caused by AAI(90).
III. Drosophina
Mutagenicity of AA was measured with Drosophila
melanogaster. AA induced sex-linked recessive lethal in
male germ cells that measured the recombinogenic activity, and mutant single spots as well as twin spots that
measured gene mutations. The results demonstrated that
AA was both a point mutagen to Drosophila and a clastogen, inducing both gene mutations and recombinogenic
activity leading to somatic recombination in mitotically
active cells (85).
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Table 3. Mutagenicity of aristolochic acid
Agent

Test system

Result

Reference

AA

Salmonella typhimurium with or without S9

Positive

(14, 15)

AAI

Salmonella typhimurium with or without S9

Positive

(86, 87)

AAII

Salmonella typhimurium with or without S9

Positive

(86, 87)

AA

Escherichia coli PQ37 genotoxicity assay with or without S9

Positive

(89)

AAI

Escherichia coli PQ37 genotoxicity assay with or without S9

Positive

(89)

AAII

Escherichia coli PQ37 genotoxicity assay with or without S9

Positive

(89)

AAI

In vitro Hprt assay in CHO cells

Positive

(87)

AAII

In vitro Hprt assay in CHO cells

Positive

(87)

AA

Mouse lymphoma assay with or without S9

Positive

(15)

AAI

In vitro Hprt assay in primary fibroblast-like rat cells

Positive

(90)

AAII

In vitro Hprt assay in primary fibroblast-like rat cells

Positive

(90)

AA

Drosophila melanogaster sex-linked recessive lethal in male
germ cells and mutant single spots

Positive

(85)

AA

Transgenic mouse lacZ and cII assays

Positive in kidney, forestomach, bladder and colon; the
major mutations are A:T →
T:C

(80)

AA

In vivo Hprt assay in subcutaneous granuloma tissue

Positive

(91)

AAI

In vivo Hprt assay in subcutaneous granuloma tissue

Positive

(90)

AAII

In vivo Hprt assay in subcutaneous granuloma tissue

Positive

(90)

AA

Transgenic rat cII assay

Positive in liver and kidney;
the major mutations are A:T
→ T:C

(70, 92)

Aristolochia
fangchi

Mutations in the p53 genes in human urothelial tumors

The major mutations detected
in the p53 gene are A:T → T:C

(41)

AAI

Human p53 DNA-binding domain mutation assay

The major mutations detected
are A:T → T:C

(98, 99)

AA

Mutation in the ras genes in rat tumors

CAA → CTA mutations were
found in c-Ha-ras, c-Ki-ras,
c-N-ras genes

(53, 54)

AAI

Mutations in ras gene in mouse tumors

CAA → CTA mutations were
found in c-Ha-ras gene

(54)

Abbreviation: aristolochic acid, AA; aristolochic acid I, AAI; aristolochic acid II, AAII.

IV. Mice
Kohara and his colleagues (80) analyzed the mutant
frequency (MF) and mutational spectra in the lacZ and
cII genes in 10 target and non-target tissues of Muta mice
intragastrically treated with 15 mg AA/kg body weight
once a week for four weeks. They found that MFs in
target tissues were significantly increased by AA over
their concurrent controls in kidney, forestomach, and
bladder (forestomach 33- and 15-fold; kidney 10- and 9fold; bladder 16- and 31-fold, for the lacZ and cII, respectively) while the MFs in non-target organs, except the
colon, showed only slight increases. Sequence analysis
of cII mutants in target organs revealed that AA induced
mainly A:T → T:A transversions whereas G:C → A:T
transitions at CpG sites predominated among sponta-

neous mutations. The authors found that MFs induced
by AA in lacZ and cII genes were correlated well with
the carcinogenic data in mice (17) so they concluded that
mutagenicity and carcinogenicity of AA were very selective to different organs.
V. Rats
Maier et al. measured the mutation induction in the
Hprt gene of rats with the Granuloma Pouch Assay. AA
was directly exposed to the subcutaneous granuloma
tissue and induced a high MF in the Hprt gene at a relatively low cytotoxic level in the target cells. The mutagenicity of AA was even more potent than N-methylN’-nitro-N-nitrosoguanidine (MNNG), a very strong
mutagen, at equimolar doses. Further study using oral
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kidney, bladder, and forestomach of AA-treated Muta
mice (80). Therefore, the treatment that does not result in
live tumors led to relatively high liver MFs, suggesting
that factors other than DNA damage and mutation are
necessary for tumor induction. A microarray analysis of
liver and kidney gene expression in rats exposed to AA
has been conducted and found that significant alteration
of genes associated with defense response, apoptosis
and immune response in kidney, but not in liver, may be
responsible for the tissue-specific toxicity and carcinogenicity of AA(95). It has also been suggested that sulpho
conjugation in liver or other tissues can be exported into
the circulation and uptaked into renal cells to cause renal
and urothelial toxicity(60).
VI. Mutagenicity of Aristolochic Acid in Oncogenes

DNA adducts per 108 nucleotides

Mutations in protooncogenes, tumor suppressor genes, and genes that function in the maintenance
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treatment of AA to rats also resulted in a dose-dependent
mutation induction in the Hprt gene (91). Maier et al. also
compared the mutagenicities of AAI and AAII using the
same method and found AAI induced 16 times more Hprt
mutants than AAII(90).
Chen et al. studied the mutagenicity of AA in rat
kidney using a protocol that resulted in tumors in order
to compare the mutagenicity of AA with its carcinogenicity(92). Groups of six male Big Blue transgenic rats were
gavaged with 0, 0.1, 1.0 and 10.0 mg AA/kg body weight
5 times a week for 12 weeks. The treatment resulted in
a significant increase in MF in the cII gene and a strong
linear dose response. The cII MFs in rat kidney were
29 × 10 -6, 78 × 10 -6, 242 × 10 -6 and 1319 × 10 -6 in the
control, low, medium and high dose treatment groups,
respectively. The dose-response for MF was consistent
with the previous carcinogenesis study (19), in which a
similar treatment with AA resulted in 0%, 27%, 86% and
100% tumor incidences in rats. The correlation between
induction of mutations and tumors by AA suggests that
AA is a potent mutagenic carcinogen. Sequence analysis of the cII mutants from AA-treated rats revealed that
A:T→T:A transversion was the predominant AA-induced
mutation. If grouping into mutations occurring at A:T
sites, a larger difference can be observed between the
treated and control groups, 73% vs. 6%. These results
support a mutagenic mechanism of action for tumor
induction by AA, considering that the same type of mutations was also found in the ras gene in rat tumors resulted
from AA treatment.
Mei et al. compared AA-induced DNA adducts and
mutations in rat liver and kidney (70) (Figure 3). Both of
the induction levels of DNA adducts and mutations are
about 2 times lower in liver than in kidney. The levels of
both DNA adducts and cII mutants detected in the nontarget liver, however, were relative high. It is known
that through AA can be activated in both the kidney and
liver (61-64,68), tumor induction by AA only occurred in
rat kidney but not in liver (19). AA-DNA adducts in AAN
patients have been observed in several organs in addition
to the urinary tract, including the liver, but AAN-associated tumors thus-far have been observed only in urothelial tissue (37,41,42). In addition, DNA adduct levels in the
liver of one patient were 9-fold lower than the kidney (37),
but in two cases DNA adducts levels in the liver were
similar to those observed in the urinary tract (41,42). It
is not clear why AA has exhibited no liver tumors in
humans or rodents. Although AA-induced DNA damage
and cll MF measured in liver in this study were only
about half of those in kidney, the induced MFs in liver
were much higher than the liver cII MFs produced by
riddelliine and comfrey, two botanical carcinogens that
induce liver tumors in rats (93,94). The overall pattern
of mutations induced by AA in liver was similar to that
in kidney(92). The main type of mutations induced in
liver by AA was also A:T → T:A transversion (54%),
which is also the predominant mutation detected in the
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Figure 3. DNA adducts and mutant f requencies induced by
aristolochic acid (AA). The open cycles indicate the results resulted
from liver while the solid cycles represent the data from kidney. Up
panel shows that DNA adducts increase with AA doses in both liver
and kidney; down panel displays that the mutant frequencies in the
cII gene enhance with doses in both liver and kidney. Data are from
literatures(70,92).
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of genomic stability are thought to be involved in the
conversion of normal somatic cells to cancer cells (96,97).
Mutagenic signatures of carcinogens found in oncogenes
can be used as finger prints to explore mechanisms of
mode of actions because mutations in these genes are the
critical steps for tumor initiation.
(I) Mutations in the p53 Gene
Lord et al. have analyzed AA-DNA adducts and
mutations in the p53 gene, a tumor-suppressor gene, on
the urothelial tumor DNA from a patient who had urothelial malignancy 6 years after presenting with AAN.
The adduct detected was dA-AAI and the p53 mutation
detected from the tumor DNA showed an AAG to TAG
mutation in codon 139 (Lys → Stop) of exon 5(41).
Cosyns et al. assessed urothelial lesions and cellular expression of p53 for 9 kidneys and ureters removed
during and/or after renal transplantation from 10
patients (36). The study shows that the intake of Chinese
herbs containing AA has a dramatic carcinogenic effect
and the carcinogenesis is associated with the overexpression of p53, which suggests a role for mutations in the p53
gene.
Liu et al. used embryonic cells from Hupki (human
p53 knock-in) mouse strain to generate human p53 DNAbinding domain (DBD) mutations experimentally. After
primary Hupki cells were exposed to AAI, 5 of the 10
established cultures harbored p53 DBD mutations. Four
out of the five mutations were A:T → T:A transversions
on the nontranscribed strand (98).
To test the hypotheses on the origins of p53 mutations in human tumors, Feldmeyer et al. developed an
assay using Hupki mouse embryonic fibroblasts (HUFs).
They examined p53 mutations induced by AAI with these
cells. Six immortalized cultures from 18 HUF primary
cultures exposed to AAI harbored p53 mutations. The
most frequently observed mutation was A:T → T:A transversion. One of the mutations was identical in position
(codon 139) and base change (A:T → T:A on the nontranscribed strand) to the single p53 mutation that has
thus far been characterized in a urothelial tumor of a
nephropathy patient with documented AAI exposure (41).
Besides, of the seven p53 mutations identified thus far
that immortalized spontaneously (no carcinogen treatment), none were A:T → T:A transversions; in addition,
no A:T → T:A transversions were identified among the
previously reported set of 18 mutations in HUF cell lines
derived from B(a)P treatment (99), suggesting that A:T →
T:A transversion is a mutagenic signature of AA exposure.
A recent study demonstrated that chronic dietary
poisoning by AA was responsible for Endemic (Balkan)
nephropathy and its associated urothelial cancer(100). AA
DNA adducts were present in renal tissues and urothelial
tumors of the patients. The AmpliChip p53 microarray
was then used to sequence exons 2–11 of the p53 gene

and 19 base substitutions in the p53 gene were found.
A:T → T:A transversions dominated the p53 mutational
spectrum in the tumors. Mutations at A:T pairs accounted for 89% of all p53 mutations, with 78% of these being
A:T → T:A transversions (100).
(II) Mutations in the ras Gene
Schmeiser et al. reported that AA activated the ras
genes in rat tumors at dA residues. They analyzed 35
various tumors from 18 male Wistar rats with long term
oral administration of AAI. They detected an activated
c-Ha-ras gene in 5 of 5 squamous cell carcinomas of the
forestomach and all of them were A:T → T:A transversions at the second position of codon 61 of the c-Ha-ras
gene (CAA to CTA). They also detected identical mutations in 93% (13 of 14) of forestomach tumors, in 100%
(7 of 7) of ear duct tumors, and in the lung metastasis.
Moreover, similar mutations were demonstrated at c-Kiras codon 61 in 1 of 7 ear duct tumors (CAA to CAT)
and in 1 of 8 tumors of the small intestine (CAA to CTA)
as well as at c-N-ras 61 (CAA to CTA) in a pancreatic
metastasis. Additional analysis revealed a CAA to CTA
transversion at codon 61 of the c-Ha-ras gene in 1 forestomach tumor as well as at codon 61 of the c-N-ras in
1 hyperplasia of the pancreas and in 1 lymphoma. The
authors suggested that dA-AAI adducts were the critical
lesions in the tumor initiation by AA(53).
Schmeiser et al. also examined the thin-tissue
sections of rat tumors induced by AAI and of mouse
tumors induced by AA for c-Ha-ras mutations in codon
61. Neoplastic and histologically normal tissues were
separated and analyzed using the PCR and mutation
detection by selective oligonucleotide hybridization.
They found A:T → T:A transversions in DNA isolated
from neoplastic tissues, but not in the adjacent normal
tissues in both rats and mice (54).

Mechanism for mutation induction
by aristolochic acid
It is clear that AA-induced DNA adduct formation results in fixation of mutations and the initiation of
tumors. AA is first metabolized to aristolactam in tissues
with specific enzymes like P450 1A1. The aristolactam
then undergo reduction of the nitro group to form reactive cyclic nitrenium ions that are able to form covalent
DNA adducts with the exocyclic amino groups of adenine
and guanine.
Among AA-DNA adducts, dA-DNA adducts are
more mutagenic for point mutation induction. If AA-DNA
adducts are not repaired before DNA synthesis during cell
proliferation, dAMP and dTMP are preferentially incorporated into the places opposite the adenine adducts, resulting A:T → T:A transversion, and A:T → A:T non-mutagenic events while dCMP was preferentially incorporated
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into the sites opposite guanine adducts, resulting in G:C
→ G:C non-mutagenic events(101,102). Therefore, the four
major types of DNA adducts preferentially produce A:T
→ T:A transversion. Both adenine adducts formed by AA
(dA-AAI and dA-AAII) have greater miscoding potential
than the guanine adducts(69,101). Besides, dA-AAI adducts
are persistent for very long time in tissues in experimental
animals and in humans while dG-AA adducts are quickly removed by DNA repair. Therefore, dA-AAI has been
suggested the most mutagenic DNA adducts for point
mutation induction.
AA-DNA adducts also result in chromosomal
damage and chromosomal mutations. AA-DNA adducts
can induce single- or double-strand breaks of DNA.
Repair of these DNA breaks can result in loss of heterozygosity, DNA deletions and insertions, chromosomal
translocations and other types of chromosomal mutations.
AA may also causes chromosomal damage via enhancing oxidative stress inside of cells. It was reported that a
significant increase in the levels of NO and the formation
of 8-OHdG in HepG2 cells (77).

Conclusions
A large body of evidence suggests that AA-induced
DNA adduct formation. Four major AA-DNA adducts,
dA-AAI, dG-AAI, dA-AAII and dG-AAII, have been
found in cell lines, in human urothelial tumors and in
tissues of animals treated with AA. Among these AADNA adducts, dA-AAI adducts has been suggested the
most mutagenic adduct.
AA is both a potent gene mutagen and a chromosomal mutagen. AA was positive in many different Salmonella typhimurium strains and induced mutations in the
Hprt and Tk genes in cell lines. It induced mutations in
the transgenic cII gene in many tissues of mice and rats,
especially in the target tissues. The major type of mutation found in rodents are A:T → T:A transversions. Mutations have been detected in the p53 and ras genes of tissues
from human tumors and rodents exposed to AA and in
AA-exposed primary mouse cells. The major type of the
mutations occurred at the oncogenes are also A:T → T:A
transversions. Also, AA is a strong clastogenic agent that
breaks DNA and results in chromosome damage and chromosome mutations. These kinds of genotoxic damage can
cause genomic instability and loss of heterozygosity of
genes that promote tumor development.
Consistence between mutations and DNA adducts
generated from tissues of animals treated with AA and
from the tumors of humans who exposed to AA suggest
that gene and chromosomal mutations induced by AA,
especially A:T → T:A transversions and chromosome
aberrations, are the causal factors in the induction of
urothelial cancer. Although it is still in the absence of
direct evidence on mutagenicity of AA in human, mutagenicity data from studies in vitro, in vivo and in onco-

genes provide sufficient evidences that mutations are
responsible for the kidney-destructive fibrotic process
and urothelial carcinogenesis.
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